Regimen Options
Last Updated: 06/03/2024 See Details
| Evolent Pathways | Febrile Neutropenic Risk | Emetogenic Risk | References | ||
|---|---|---|---|---|---|
| HODGKIN LYMPHOMA - CLASSICAL | |||||
Primary/Initial Therapy (Low Risk) |
OEPA |
High | Moderate |
|
|
Primary/Initial Therapy (Intermediate Risk) |
OEPA |
High | Moderate |
|
|
ABVE-PC |
High | Moderate |
|
||
Primary/Initial Therapy (High Risk) |
OEPA |
High | Moderate |
|
|
ABVE-PC |
High | Moderate |
|
||
BV-AVE-PC |
High | Moderate |
|
||
Relapsed/Refractory |
ICE |
High | High |
|
|
| NODULAR LYMPHOCYTE PREDOMINANT (NLPHL) | |||||
Primary/Initial Therapy |
AVPC |
Low | Low |
|
|
HODGKIN LYMPHOMA - CLASSICAL
Primary/Initial Therapy (Low Risk)
Evolent Pathways
OEPA
Febrile Neutropenic Risk
high
Emetogenic Risk
moderate
References
Primary/Initial Therapy (Intermediate Risk)
Evolent Pathways
OEPA
Febrile Neutropenic Risk
high
Emetogenic Risk
moderate
References
Evolent Pathways
ABVE-PC
Febrile Neutropenic Risk
high
Emetogenic Risk
moderate
References
Primary/Initial Therapy (High Risk)
Evolent Pathways
OEPA
Febrile Neutropenic Risk
high
Emetogenic Risk
moderate
References
Evolent Pathways
ABVE-PC
Febrile Neutropenic Risk
high
Emetogenic Risk
moderate
References
Evolent Pathways
BV-AVE-PC
Febrile Neutropenic Risk
high
Emetogenic Risk
moderate
References
Relapsed/Refractory
Evolent Pathways
ICE
Febrile Neutropenic Risk
high
Emetogenic Risk
high
References
NODULAR LYMPHOCYTE PREDOMINANT (NLPHL)
Primary/Initial Therapy
Evolent Pathways
AVPC
Febrile Neutropenic Risk
low
Emetogenic Risk
low
References